The director of the Chumakov Center called the statements about the effectiveness of KoviVac premature

At the moment, it is premature to talk about the level of effectiveness of the vaccine against the coronavirus “KoviVac”, said Director General of the Chumakov Center, Corresponding Member of the Russian Academy of Sciences Aydar Ishmukhametov. Mr. Ishmukhametov explained that this will become clear only after the completion of all phases of testing. At the same time, the stand of the Ministry of Education and Science at the St. Petersburg International Economic Forum (SPIEF) stated that the effectiveness of the drug exceeds 80%.

“Until the vaccine created by our specialists passes the third phase of trials, it is too early to talk about the level of its effectiveness. The CoviVac efficiency figures cited today are just value judgments. According to preliminary results of clinical trials of the second phase, about 80% of the volunteers developed antibodies, ”he said on the sidelines of the SPIEF (quoted by TASS).

The fact that the vaccine “KoviVac” arrived in Moscow and the regions became known the day before. She can be vaccinated in the near future. The Moscow health department clarified that 3 thousand doses of the drug are already available in the city. Before that, Muscovites could be vaccinated with Sputnik V and EpiVacCorona.

How “KoviVak” differs from other vaccines against coronavirus – in the material “Kommersant FM”.